

Supplemental Figure 1: Kinetics of the percentage for CD4+/Foxp3+ T cells in the liver.

Mice bearing hepatic metastases of CT26 were left untreated (NT), treated with LM-D, Cy, or both as in Figure 4. Livers from each group were harvested at 3 time points, 9, 14, and 21 days after tumor challenge and processed for flow cytometry analysis. The percentages/liver were checked at different time points for CD4+/Foxp3+ T cells.

Supplemental Figure 2: Kinetics of the percentage for CD4+/Foxp3+ T cells in the spleen.

Mice bearing hepatic metastases of CT26 were left untreated (NT), treated with LM-D, Cy, or both as in Figure 4. Spleens from each group were harvested at 3 time points, 9, 14, and 21 days after tumor challenge and processed for flow cytometry analysis. The percentages/spleen were checked at different time points for CD4+/Foxp3+ T cells.

Supplemental Figure 3: Kinetics of CD4+, CD8+, and CD4/Foxp3+ cells from spleen populations in mice bearing hepatic metastases.

Mice bearing hepatic metastases of CT26 were left untreated (NT), treated with LM-D, Cy, or both as in Figure 4. Spleens from each group were harvested at 3 time points, 9, 14, and 21 days after tumor challenge and processed for flow cytometry analysis. Total cells/spleen were enumerated at different time points for CD4+ T cells (A), CD8+ T cells (B), and CD4+/Foxp3+ T cells (C).